Vanda Pharmaceuticals (VNDA) EBT Margin (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly EBT Margin of 93.63% in Q1 2026, down 40.97% quarter-over-quarter from 66.42% in Q4 2025, and down 1896.0% year-over-year from 5.21% in Q1 2025.
Vanda Pharmaceuticals' EBT Margin history runs 17 years deep, the most recent figure standing at 93.63% for Q1 2026.
- In Q1 2026, EBT Margin fell 1896.0% year-over-year to 93.63%; the TTM figure through Mar 2026 stood at 68.74% (down 4111.0% YoY), while the FY2025 annual figure was 64.16%, down 5263.0% from the prior year.
- EBT Margin came in at 93.63% for Q1 2026 at Vanda Pharmaceuticals, down from 66.42% in the prior quarter.
- In the past five years, EBT Margin ranged from a high of 14.91% in Q4 2022 to a low of 93.63% in Q1 2026.
- A 5-year average of 21.8% and a median of 10.93% in 2024 frame the typical range for EBT Margin.
- Across the five-year window, EBT Margin jumped 2141 bps in 2023 and plunged 6485 bps in 2025, its largest moves.
- Vanda Pharmaceuticals' EBT Margin stood at 14.91% in 2022, then slumped by 125 bps to 3.67% in 2023, then plunged by 233 bps to 12.22% in 2024, then slumped by 444 bps to 66.42% in 2025, then sank by 41 bps to 93.63% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 93.63%, 66.42%, and 50.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -6.40% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 41.95% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.05% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 18.99% |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -93.63% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -93.63% |
| Dec 31, 2025 | -66.42% |
| Sep 30, 2025 | -50.46% |
| Jun 30, 2025 | -66.34% |
| Mar 31, 2025 | -74.67% |
| Dec 31, 2024 | -12.22% |
| Sep 30, 2024 | -13.10% |
| Jun 30, 2024 | -10.93% |
| Mar 31, 2024 | -9.83% |
| Dec 31, 2023 | -3.67% |
| Sep 30, 2023 | -0.31% |
| Jun 30, 2023 | 5.63% |
| Mar 31, 2023 | 8.85% |
| Dec 31, 2022 | 14.91% |
| Sep 30, 2022 | 8.36% |
| Jun 30, 2022 | 5.89% |
| Mar 31, 2022 | -12.57% |
| Dec 31, 2021 | 12.66% |
| Sep 30, 2021 | 15.30% |
| Jun 30, 2021 | 18.56% |
| Mar 31, 2021 | 16.64% |
| Dec 31, 2020 | 16.15% |
| Sep 30, 2020 | 13.93% |
| Jun 30, 2020 | 17.83% |
| Mar 31, 2020 | 2.14% |
| Dec 31, 2019 | 9.54% |
| Sep 30, 2019 | 20.64% |
| Jun 30, 2019 | 19.55% |
| Mar 31, 2019 | -1.26% |
| Dec 31, 2018 | 19.45% |
| Sep 30, 2018 | 14.78% |
| Jun 30, 2018 | 9.93% |
| Mar 31, 2018 | 7.03% |
| Dec 31, 2017 | -3.95% |
| Sep 30, 2017 | -10.95% |
| Jun 30, 2017 | -3.63% |
| Mar 31, 2017 | -20.38% |
| Dec 31, 2016 | -1.31% |
| Sep 30, 2016 | -1.12% |
| Jun 30, 2016 | -12.82% |
| Mar 31, 2016 | -37.15% |
| Dec 31, 2015 | -46.76% |
| Sep 30, 2015 | -33.66% |
| Jun 30, 2015 | -19.79% |
| Mar 31, 2015 | -46.47% |
| Dec 31, 2014 | 453.44% |
| Sep 30, 2014 | -9.80% |
| Jun 30, 2014 | -198.63% |
| Mar 31, 2014 | -290.20% |
| Dec 31, 2013 | -86.79% |
| Sep 30, 2013 | -61.78% |
| Jun 30, 2013 | -40.67% |
| Mar 31, 2013 | -56.01% |
| Dec 31, 2012 | 256.84% |
| Sep 30, 2012 | -64.26% |
| Jun 30, 2012 | -95.57% |
| Mar 31, 2012 | -97.80% |
| Dec 31, 2011 | -69.40% |
| Sep 30, 2011 | -39.99% |
| Jun 30, 2011 | -18.73% |
| Mar 31, 2011 | 1.89% |
| Dec 31, 2010 | -19.43% |
| Sep 30, 2010 | 12.41% |
| Jun 30, 2010 | 80.61% |